接受促性腺激素释放激素类似物治疗前列腺腺癌患者的血清催乳素水平。
Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate.
作者信息
Siegel Y I, Korczak D, Lindner A
机构信息
Urology Department, Edith Wolfson Medical Center, Holon, Israel.
出版信息
Eur Urol. 1991;19(1):16-8. doi: 10.1159/000473571.
Twenty-six patients with advanced cancer of the prostate were treated with [D-SER(BUt)6]LHRH-(1-9) nonapeptide ethylamide (buserelin). All but 6 patients evidenced signs of metastasis. Blood prolactin levels were measured prior to the initiation of treatment and during a follow-up period of 18 months. A statistically significant (p greater than 0.0005) elevation in serum prolactin levels was observed after 3 months of treatment. Serum prolactin remained elevated for a total of 6 months, after which a decline to pretreatment levels was observed. Our observation of a transient rise in prolactin levels during the chronic administration of buserelin is at variance with previously published data which reported unchanged prolactin levels during such treatment.
26例晚期前列腺癌患者接受了[D-丝氨酸（叔丁基）6]促黄体生成素释放激素（1-9）九肽乙酰胺（布舍瑞林）治疗。除6例患者外，其余患者均有转移迹象。在治疗开始前及18个月的随访期内测定血催乳素水平。治疗3个月后，血清催乳素水平出现统计学显著升高（p>0.0005）。血清催乳素总共升高了6个月，之后降至治疗前水平。我们观察到在长期给予布舍瑞林期间催乳素水平短暂升高，这与之前发表的数据不一致，之前的数据报道在此类治疗期间催乳素水平无变化。
Zotero 插件